T. Rowe Price Associates
IMGO

T. Rowe Price Associates’s Imago BioSciences, Inc. Common stock IMGO Stock Holding History

T. Rowe Price Associates’s Portfolio IMGO Stock Details IMGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,885,112
Closed -$28.4M – 3021
2022
Q3 		$28.4M Sell
1,885,112
-35,198
-2% -$571K ﹤0.01% 801
2022
Q2 		$25.7M Sell
1,920,310
-251,925
-12% -$4M ﹤0.01% 1102
2022
Q1 		$41.9M Sell
2,172,235
-69,682
-3% -$1.45M ﹤0.01% 1031
2021
Q4 		$51.4M Buy
2,241,917
+38,313
+2% +$888K ﹤0.01% 994
2021
Q3 		$42.7M Buy
+2,203,604
New +$47.3M ﹤0.01% 1076

Other funds holding IMGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

T. Rowe Price Associates's IMGO Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Imago BioSciences, Inc. Common stock (IMGO) in Q4 2022, closing a stake of 1,885,112 shares — an estimated $28.4M sold.

T. Rowe Price Associates first reported a position in IMGO in Q3 2021 and held it in 5 quarters. The position peaked at $51.4M in Q4 2021. 106 funds tracked by Wall St. Rank hold IMGO as of Q4 2022.

  • T. Rowe Price Associates reported no remaining Imago BioSciences, Inc. Common stock position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,885,112 Imago BioSciences, Inc. Common stock shares in Q4 2022, an estimated $28.4M.
  • T. Rowe Price Associates first reported a position in Imago BioSciences, Inc. Common stock in Q3 2021 and held it in 5 quarters.
  • T. Rowe Price Associates's Imago BioSciences, Inc. Common stock position peaked at $51.4M in Q4 2021.
  • 106 funds tracked by Wall St. Rank held Imago BioSciences, Inc. Common stock as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.